Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis [0.03%]
欧盟临床试验新法规下的儿科I/II期临床试验评估:一项描述性分析
Laura Fankhauser,Franca Ligas,Giovanni Lesa et al.
Laura Fankhauser et al.
Background: Children remain underrepresented in clinical research, despite regulatory frameworks like the EU Paediatric Regulation and Paediatric Investigation Plans (PIPs). The 2024 Declaration of Helsinki revision now r...
Transformation of a Medical Information Department to Meet the New Healthcare Realities of the Post-Pandemic Era [0.03%]
后疫情时代转型适应新的医疗卫生环境的医学信息科
Almudena Rovirosa,Sara Jericó,Ana Muñiz et al.
Almudena Rovirosa et al.
The role of Medical Information in the pharmaceutical industry is undergoing a profound transformation, driven by evolving stakeholder expectations, digital innovation, and the increasing complexity of therapeutic landscapes. Traditionally ...
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation [0.03%]
一种具有口味掩蔽和剂量灵活性的儿童多单元固体分散制剂的开发:以克唑替尼为研究对象的案例分析
Jeremy A Bartlett,Natalie Culver,Matt Santangelo et al.
Jeremy A Bartlett et al.
Background: Developing pediatric dosage forms remains challenging, particularly for poorly palatable drugs, which can limit tolerability and adherence. Crizotinib, an anaplastic lymphoma kinase inhibitor used to treat rar...
Association Between Survival Benefits of Anticancer Drugs and Probability of US Food and Drug Administration Approval: A Systematic Review [0.03%]
抗癌药物的生存益处及其获得美国食品药品监督管理局批准的概率之间的关系:系统性综述
Koji Ishizuka,Shunsuke Ono
Koji Ishizuka
BACKGROUND AND OBJECTIVES: Survival benefit constitutes the primary pillar of therapeutic efficacy in oncology. However, the survival benefits observed in registrational trials broadly range from significant to marginal, even for US Food an...
The Combat Against Antimicrobial Resistance: An Overview of EU Recent Health Policies and Drug Regulations Promoting the Development of New Antimicrobials [0.03%]
对抗微生物耐药性的斗争:促进新型抗菌药物研发的欧盟近期卫生政策和药品监管综述
Lena Daher,Ingrid Vilimelis-Piulats
Lena Daher
Antimicrobial resistance, including antibiotic resistance, constitutes a major global public health threat. In Europe, antimicrobial resistance is recognized among the top three health threats, in line with the World Health Organization's p...
38th Congress of the European College of Neuropsychopharmacology (ECNP 2025) [0.03%]
第38届欧洲神经精神药理学学院年会(ECNP 2025)
Alma Orts-Sebastian
Alma Orts-Sebastian
Shaping the Future of Evidence Generation: Real-World Data to Drive Healthcare Transformation and Patient-Centered Decisions [0.03%]
塑造证据生成的未来:利用真实世界数据推动医疗转型和以患者为中心的决策
Jesús Medina,Joaquín Sánchez-Covisa,Javier Nuevo et al.
Jesús Medina et al.
The increasing complexity of healthcare decision making and the demand for real-world evidence call for a transformation in how Medical Affairs departments generate and communicate evidence. In response, AstraZeneca Spain implemented a stru...
Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia [0.03%]
超越毛囊:系统性疾病和药物如何影响脱发的叙事性回顾
Debalina Bose,Depti Bellani,Raji Patil et al.
Debalina Bose et al.
Alopecia is a multifactorial condition resulting from the convergence of systemic pathologies, pharmacologic exposures, genetic predispositions, and environmental factors. Among these, systemic diseases and medications play a prominent role...
Best Practices for Medical Information Global Response Documents from phactMI and MILE [0.03%]
PMEI和MILE的《全球响应文档医学信息最佳实践》
Susan Wnorowski,Faith Niemoller,Anja Glaetzer et al.
Susan Wnorowski et al.
Medical information departments within pharmaceutical companies play a critical role in addressing unsolicited healthcare professionals' inquires with accurate, evidence-based, and balanced medical information through scientific response do...
Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices [0.03%]
公开发布的临床试验安全性数据:综述及对标准化和改进报告实践的呼吁
Barbara A Hendrickson,Cynthia McShea,Tarek A Hammad et al.
Barbara A Hendrickson et al.
Background and objectives: Comprehensible reporting of clinical trial safety data is essential for multiple stakeholders, including ongoing safety reporting by sponsors to the health authorities. However, the consistency ...